BCM
REGN icon

Bronte Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bronte Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8M Hold
68,600
– – 4.59% 8
2026
Q1 		$53M Buy
68,600
+9,300
+16% +$7.12M 5.24% 8
2025
Q4 		$45.8M Buy
+59,300
New +$40.3M 4.57% 8

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bronte Capital Management's REGN Position: Q2 2026 in Review

Bronte Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 5.9% in Q2 2026, selling an estimated $6.92M and leaving 162,618 shares worth $101M. The position accounts for 10.89% of the portfolio, ranked #2.

Bronte Capital Management first reported a position in REGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $147M in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bronte Capital Management held 162,618 shares of Regeneron Pharmaceuticals worth $101M as of Q2 2026.
  • Bronte Capital Management sold 10,169 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.92M.
  • Regeneron Pharmaceuticals made up 10.89% of Bronte Capital Management's portfolio in Q2 2026, its #2 holding.
  • Bronte Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bronte Capital Management's Regeneron Pharmaceuticals position peaked at $147M in Q2 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.